Lineage Cell Therapeutics (LCTX) Change in Acquisitions & Divestments (2023 - 2026)

Lineage Cell Therapeutics has reported Change in Acquisitions & Divestments for 4 years, with the latest figure at $6.0 million in Q1 2026.

• For the quarter ending Q1 2026, Change in Acquisitions & Divestments rose 198.25% year-over-year to $6.0 million; the trailing twelve-month figure through Mar 2026 stood at $6.0 million (up 195.59% YoY), and the FY2025 full-year result was $2.0 million, up 11011.11% from the prior year.
• Change in Acquisitions & Divestments for Q1 2026 stood at $6.0 million, up from $2.0 million in the prior quarter.
• The five-year high for Change in Acquisitions & Divestments was $24.3 million in Q2 2023, with the low at -$4.0 million in Q4 2024.
• Historically, Change in Acquisitions & Divestments has averaged $8.9 million across 4 years, with a median of $5.9 million in 2023.
• Annual changes were most pronounced in 2024 — Change in Acquisitions & Divestments tumbled 140.5% — and 2026, when it soared 198.25%.
• Lineage Cell Therapeutics' Change in Acquisitions & Divestments stood at $9.8 million in 2023, then plunged by 140.5% to -$4.0 million in 2024, then surged by 150.23% to $2.0 million in 2025, then soared by 198.25% to $6.0 million in 2026.
• The last three Change in Acquisitions & Divestments figures came in at $6.0 million (Q1 2026), $2.0 million (Q1 2025), and -$4.0 million (Q4 2024), per Business Quant data.